INVA
Price
$21.06
Change
+$0.15 (+0.72%)
Updated
Oct 22 closing price
Capitalization
1.52B
13 days until earnings call
Intraday BUY SELL Signals
KNSA
Price
$80.79
Change
+$1.09 (+1.37%)
Updated
Oct 22 closing price
Capitalization
6.3B
5 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

INVA vs KNSA

INVA vs KNSA Comparison Chart in %
View a ticker or compare two or three
VS
INVA vs. KNSA commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INVA is a Buy and KNSA is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for INVA with price predictions
Oct 22, 2026

INVA in upward trend: price rose above 50-day moving average on October 22, 2026

INVA moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend. In 25 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 64%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on INVA as a result. In 41 of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.

The Moving Average Convergence Divergence (MACD) for INVA just turned positive on October 07, 2026. Looking at past instances where INVA's MACD turned positive, the stock continued to rise in 28 of 44 cases over the following month. The odds of a continued upward trend are 64%.

The 10-day moving average for INVA crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 57%.

Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where INVA advanced for three days, in 187 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

INVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 111 of 204 cases where INVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 55 cases where INVA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 64%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. INVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.234) is normal, around the industry mean (2.973). P/E Ratio (4.089) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (3.173) is also within normal values, averaging (9.059). Dividend Yield (0.047) settles around the average of (128.121) among similar stocks. P/S Ratio (4.092) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
a Summary for KNSA with price predictions
Oct 22, 2026

KNSA in upward trend: price rose above 50-day moving average on October 07, 2026

KNSA moved above its 50-day moving average on October 07, 2026 date and that indicates a change from a downward trend to an upward trend. In 26 of 31 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on KNSA as a result. In 71 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.

The Moving Average Convergence Divergence (MACD) for KNSA just turned positive on October 07, 2026. Looking at past instances where KNSA's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.

The 10-day moving average for KNSA crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.

Following a +5.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where KNSA advanced for three days, in 232 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

The 10-day RSI Indicator for KNSA moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In 36 of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 67 cases where KNSA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KNSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

KNSA broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for KNSA entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. KNSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.636) is normal, around the industry mean (10.407). P/E Ratio (76.217) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (7.564) is also within normal values, averaging (178.797).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

FUNDAMENTALS RATINGS
INVA vs KNSA: Fundamental Ratings
INVA
KNSA
OUTLOOK RATING
1..100
1441
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
662
SMR RATING
1..100
2859
PRICE GROWTH RATING
1..100
5535
P/E GROWTH RATING
1..100
9696
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KNSA's Valuation (79) in the Pharmaceuticals Major industry is in the same range as INVA (84) in the Pharmaceuticals Other industry. This means that KNSA’s stock grew similarly to INVA’s over the last 12 months.

KNSA's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is somewhat better than the same rating for INVA (66) in the Pharmaceuticals Other industry. This means that KNSA’s stock grew somewhat faster than INVA’s over the last 12 months.

INVA's SMR Rating (28) in the Pharmaceuticals Other industry is in the same range as KNSA (59) in the Pharmaceuticals Major industry. This means that INVA’s stock grew similarly to KNSA’s over the last 12 months.

KNSA's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as INVA (55) in the Pharmaceuticals Other industry. This means that KNSA’s stock grew similarly to INVA’s over the last 12 months.

KNSA's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as INVA (96) in the Pharmaceuticals Other industry. This means that KNSA’s stock grew similarly to INVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INVAKNSA
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
75%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
64%
Bearish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
55%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
64%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
59%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
58%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
63%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 7 days ago
64%
Bearish Trend 10 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
64%
Bearish Trend 1 day ago
73%
Aroon
ODDS (%)
Bullish Trend 1 day ago
54%
Bearish Trend 1 day ago
68%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (INVA: $21.06 vs. KNSA: $79.70)
Brand notoriety: INVA and KNSA are both not notable
INVA represents the Biotechnology, while KNSA is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: INVA: 60% vs. KNSA: 167%
Market capitalization -- INVA: $1.52B vs. KNSA: $6.3B
INVA [@Biotechnology] is valued at $1.52B. KNSA’s [@Pharmaceuticals: Generic] market capitalization is $6.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Biotechnology] industry is $2.14B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INVA’s FA Score shows that 1 FA rating(s) are green while KNSA’s FA Score has 1 green FA rating(s).

  • INVA’s FA Score: 1 green, 4 red.
  • KNSA’s FA Score: 1 green, 4 red.
According to our system of comparison, KNSA is a better buy in the long-term than INVA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INVA’s TA Score shows that 7 TA indicator(s) are bullish while KNSA’s TA Score has 5 bullish TA indicator(s).

  • INVA’s TA Score: 7 bullish, 2 bearish.
  • KNSA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, INVA is a better buy in the short-term than KNSA.

Price Growth

INVA (@Biotechnology) experienced а +0.96% price change this week, while KNSA (@Pharmaceuticals: Generic) price change was +1.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.

Reported Earning Dates

INVA is expected to report earnings on Nov 04, 2026.

KNSA is expected to report earnings on Oct 27, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (-2.94% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
INVA
Daily Signal:
Gain/Loss:
KNSA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

KNSA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with COYA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then COYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNSA
1D Price
Change %
KNSA100%
+1.37%
COYA - KNSA
42%
Loosely correlated
N/A
ABVC - KNSA
40%
Loosely correlated
+4.00%
JBIO - KNSA
37%
Loosely correlated
-1.45%
AMRN - KNSA
36%
Loosely correlated
+0.78%
SNDX - KNSA
35%
Loosely correlated
+3.19%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FDL53.341.46
+2.81%
First Trust Morningstar Dividend Leaders Index Fund (FDL)
KAT59.670.17
+0.28%
Scharf ETF (KAT)
BAIV28.630.04
+0.12%
Brown Advisory International Value Select ETF (BAIV)
COAL23.82-0.16
-0.67%
Range Global Coal Index ETF (COAL)
ACTS24.46-0.81
-3.21%
FIS Tactical Equity ETF (ACTS)